Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal
<strong>Background</strong> The 2014 West African outbreak of Ebola virus disease highlighted the urgent need to develop an effective Ebola vaccine. <strong>Methods</strong> We undertook two Phase I studies assessing safety and immunogenicity of the viral vector MVA-EBO-Z, m...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Oxford University Press
2018
|
| _version_ | 1797084928873070592 |
|---|---|
| author | Venkatraman, N Ndiaye, B Bowyer, G Wade, D Sridhar, S Wright, D Powlson, J Ndiaye, I Dièye, S Thompson, C Bakhoum, M Morter, R Capone, S Del Sorbo, M Jamieson, S Rampling, T Dattoo, M Roberts, R Poulton, I Griffiths, O Ballou, W Roman, F Lewis, DJM Lawrie, A Imoukhuede, E Gilbert, S Dieye, TN Ewer, KJ Hill, A Mboup, S |
| author_facet | Venkatraman, N Ndiaye, B Bowyer, G Wade, D Sridhar, S Wright, D Powlson, J Ndiaye, I Dièye, S Thompson, C Bakhoum, M Morter, R Capone, S Del Sorbo, M Jamieson, S Rampling, T Dattoo, M Roberts, R Poulton, I Griffiths, O Ballou, W Roman, F Lewis, DJM Lawrie, A Imoukhuede, E Gilbert, S Dieye, TN Ewer, KJ Hill, A Mboup, S |
| author_sort | Venkatraman, N |
| collection | OXFORD |
| description | <strong>Background</strong> The 2014 West African outbreak of Ebola virus disease highlighted the urgent need to develop an effective Ebola vaccine. <strong>Methods</strong> We undertook two Phase I studies assessing safety and immunogenicity of the viral vector MVA-EBO-Z, manufactured rapidly on a new duck cell line either alone or in a heterologous prime-boost regimen with ChAd3-EBO-Z followed by MVA-EBO-Z. Adult volunteers in the UK (n = 38) and Senegal (n=40) were vaccinated and an accelerated one week prime-boost regimen was assessed in Senegal. Safety was assessed by active and passive collection of local and systemic adverse events. <strong>Results</strong> The standard and accelerated heterologous prime-boost regimes were well-tolerated and elicited potent cellular and humoral immunogenicity in the UK and Senegal, but vaccine-induced antibody responses were significantly lower in Senegal. Cellular immune responses measured by flow cytometry were significantly greater in African vaccinees receiving ChAd3 and MVA vaccines in the same rather than the contralateral limb. <strong>Conclusions</strong> MVA biomanufactured on an immortalised duck cell line shows potential for very large-scale manufacturing with lower cost of goods. This first trial of MVA-EBO-Z in humans encourages further testing in Phase II studies with the one week prime-boost interval regimen appearing particularly suitable for outbreak control. |
| first_indexed | 2024-03-07T02:02:01Z |
| format | Journal article |
| id | oxford-uuid:9db12d3e-9bd4-4267-a266-db473d003d13 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T02:02:01Z |
| publishDate | 2018 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:9db12d3e-9bd4-4267-a266-db473d003d132022-03-27T00:44:58ZSafety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and SenegalJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9db12d3e-9bd4-4267-a266-db473d003d13Symplectic Elements at OxfordOxford University Press2018Venkatraman, NNdiaye, BBowyer, GWade, DSridhar, SWright, DPowlson, JNdiaye, IDièye, SThompson, CBakhoum, MMorter, RCapone, SDel Sorbo, MJamieson, SRampling, TDattoo, MRoberts, RPoulton, IGriffiths, OBallou, WRoman, FLewis, DJMLawrie, AImoukhuede, EGilbert, SDieye, TNEwer, KJHill, AMboup, S<strong>Background</strong> The 2014 West African outbreak of Ebola virus disease highlighted the urgent need to develop an effective Ebola vaccine. <strong>Methods</strong> We undertook two Phase I studies assessing safety and immunogenicity of the viral vector MVA-EBO-Z, manufactured rapidly on a new duck cell line either alone or in a heterologous prime-boost regimen with ChAd3-EBO-Z followed by MVA-EBO-Z. Adult volunteers in the UK (n = 38) and Senegal (n=40) were vaccinated and an accelerated one week prime-boost regimen was assessed in Senegal. Safety was assessed by active and passive collection of local and systemic adverse events. <strong>Results</strong> The standard and accelerated heterologous prime-boost regimes were well-tolerated and elicited potent cellular and humoral immunogenicity in the UK and Senegal, but vaccine-induced antibody responses were significantly lower in Senegal. Cellular immune responses measured by flow cytometry were significantly greater in African vaccinees receiving ChAd3 and MVA vaccines in the same rather than the contralateral limb. <strong>Conclusions</strong> MVA biomanufactured on an immortalised duck cell line shows potential for very large-scale manufacturing with lower cost of goods. This first trial of MVA-EBO-Z in humans encourages further testing in Phase II studies with the one week prime-boost interval regimen appearing particularly suitable for outbreak control. |
| spellingShingle | Venkatraman, N Ndiaye, B Bowyer, G Wade, D Sridhar, S Wright, D Powlson, J Ndiaye, I Dièye, S Thompson, C Bakhoum, M Morter, R Capone, S Del Sorbo, M Jamieson, S Rampling, T Dattoo, M Roberts, R Poulton, I Griffiths, O Ballou, W Roman, F Lewis, DJM Lawrie, A Imoukhuede, E Gilbert, S Dieye, TN Ewer, KJ Hill, A Mboup, S Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal |
| title | Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal |
| title_full | Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal |
| title_fullStr | Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal |
| title_full_unstemmed | Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal |
| title_short | Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the United Kingdom and Senegal |
| title_sort | safety and immunogenicity of a heterologous prime boost ebola virus vaccine regimen in healthy adults in the united kingdom and senegal |
| work_keys_str_mv | AT venkatramann safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT ndiayeb safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT bowyerg safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT waded safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT sridhars safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT wrightd safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT powlsonj safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT ndiayei safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT dieyes safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT thompsonc safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT bakhoumm safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT morterr safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT capones safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT delsorbom safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT jamiesons safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT ramplingt safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT dattoom safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT robertsr safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT poultoni safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT griffithso safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT ballouw safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT romanf safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT lewisdjm safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT lawriea safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT imoukhuedee safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT gilberts safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT dieyetn safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT ewerkj safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT hilla safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal AT mboups safetyandimmunogenicityofaheterologousprimeboostebolavirusvaccineregimeninhealthyadultsintheunitedkingdomandsenegal |